Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Emma Guttman
Observed name:
E. Guttman
Institution:
Icahn School of Medicine at Mount Sinai
Observed institution:
Icahn School of Medicine at Mount Sinai
ORCID:
0000-0002-9363-324X
Observed ORCID:
0000-0002-9363-324X
OpenAlex ID:
A5114205499
Pharmacology of orismilast, a potent and selective PDE4 inhibitor
2022
·
Jonathan I. Silverberg
, Lars E. French
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
44
PDF
Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets
2022
·
Richard B. Warren
, Bruce Strober
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
27
PDF
Major depressive disorder shares systemic immune signatures and potential therapeutic targets with inflammatory skin diseases
2026
·
Helen He
, Flurin Cathomas
, et al.
·
Molecular Psychiatry
·
11
PDF
533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis including over 7000 patient-years of exposure
2024
·
Christopher Bunick
, Raj Chovatiya
, et al.
·
British Journal of Dermatology
·
11
63852 Flare Occurrence and Healthcare Resource Utilization Among Patients Who Achieve Minimal Disease Activity in Atopic Dermatitis: Results from a Real-world Multi-country Study
2025
·
Jonathan Silverberg
, Vimal Prajapati
, et al.
·
Journal of the American Academy of Dermatology
·
1
693 - Efficacy and safety of orismilast, a potent PDE4B/D inhibitor, in adults with moderate-to-severe atopic dermatitis: a phase 2b randomized, double-blind, placebo-controlled clinical trial (ADESOS)
2024
·
Jonathan Silverberg
, Lawrence Eichenfield
, et al.
·
British Journal of Dermatology
·
1
Fréquence des poussées et dépenses relatives aux soins chez les patients atteignant une activité minimale de la maladie dans la dermatite atopique : résultats d’une étude multicentrique en vie réelle
2025
·
J.I. Silverberg
, V.H. Prajapati
, et al.
·
Annales de Dermatologie et de Vénéréologie - FMC
L’amlitélimab réduit l’expression génique associée aux réponses inflammatoires Th2-, Th1 et Th17/22 chez les adultes atteints de dermatite atopique modérée à sévère : résultats d’une analyse exploratoire de l’étude de phase 2b STREAM-AD
2025
·
B. Geng
, K. Eyerich
, et al.
·
Annales de Dermatologie et de Vénéréologie - FMC
59637 Evaluation of Darier Sign in Cutaneous Mastocytoma by Reflectance Confocal Microscopy
2025
·
Jeremy Orloff
, Serena Morsia
, et al.
·
Journal of the American Academy of Dermatology
638 - Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial
2024
·
Eric L Simpson
, Lawrence F Eichenfield
, et al.
·
British Journal of Dermatology
Show more works
View as search
Works count:
10
Citation count:
95
H-index:
4
I10-index:
4
Year
Topic
Type